Biotech News
Related news
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ERASErasca2026-07-14 03:10 EST
Erasca Announces Pricing of Upsized Public Offering of Common Stock
ELVNEnliven Therapeutics2026-06-11 20:05 EST
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
ELVNEnliven Therapeutics2026-06-15 20:40 EST
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
LEGNLegend Biotech Corporation2026-06-17 20:29 EST
Legend Biotech Corporation Announces Proposed Public Offering
IDYAIDEAYA Biosciences2026-06-10 20:05 EST
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
LEGNLegend Biotech Corporation2026-06-18 01:21 EST
Legend Biotech Corporation Announces Pricing of Public Offering
INBXInhibrx2026-07-16 13:00 EST
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
NRIXNurix Therapeutics2026-08-04 11:00 EST
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct and pathway-level inhibition. ERAS-0015 ERAS-0015 is a RAS-targeted clinical candidate being evaluated in tumors...
Recent company news
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ERASErasca2026-07-14 03:10 EST
Erasca Announces Pricing of Upsized Public Offering of Common Stock
ERASErasca2026-07-13 20:19 EST
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
ERASErasca2026-07-13 20:01 EST
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERASErasca2026-05-27 12:00 EST
Erasca to Present at the Jefferies Global Healthcare Conference
Stock data
- Close
- 18.27 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States